315 related articles for article (PubMed ID: 38443363)
1. Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma.
Fei C; Zhen X; Shiqiang Z; Jun P
Cell Death Discov; 2024 Mar; 10(1):113. PubMed ID: 38443363
[TBL] [Abstract][Full Text] [Related]
2. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research.
Tong X; Tang R; Xiao M; Xu J; Wang W; Zhang B; Liu J; Yu X; Shi S
J Hematol Oncol; 2022 Dec; 15(1):174. PubMed ID: 36482419
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Tang R; Xu J; Zhang B; Liu J; Liang C; Hua J; Meng Q; Yu X; Shi S
J Hematol Oncol; 2020 Aug; 13(1):110. PubMed ID: 32778143
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Diversity and complexity of cell death: a historical review.
Park W; Wei S; Kim BS; Kim B; Bae SJ; Chae YC; Ryu D; Ha KT
Exp Mol Med; 2023 Aug; 55(8):1573-1594. PubMed ID: 37612413
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer.
Zhang C; Liu N
Front Immunol; 2022; 13():920059. PubMed ID: 35958626
[TBL] [Abstract][Full Text] [Related]
7. Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy.
Lai Y; Zeng T; Liang X; Wu W; Zhong F; Wu W
Cancer Cell Int; 2019; 19():221. PubMed ID: 31462894
[TBL] [Abstract][Full Text] [Related]
8. A Ferroptosis-Related Genes Model Allows for Prognosis and Treatment Stratification of Clear Cell Renal Cell Carcinoma: A Bioinformatics Analysis and Experimental Verification.
Wu J; Sun Z; Bi Q; Wang W
Front Oncol; 2022; 12():815223. PubMed ID: 35155251
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
Front Genet; 2022; 13():938259. PubMed ID: 35910212
[No Abstract] [Full Text] [Related]
10. Beyond apoptosis: evidence of other regulated cell death pathways in the ovary throughout development and life.
Stringer JM; Alesi LR; Winship AL; Hutt KJ
Hum Reprod Update; 2023 Jul; 29(4):434-456. PubMed ID: 36857094
[TBL] [Abstract][Full Text] [Related]
11. Ferroptosis in tumors and its relationship to other programmed cell death: role of non-coding RNAs.
Zhang Q; Fan X; Zhang X; Ju S
J Transl Med; 2023 Jul; 21(1):514. PubMed ID: 37516888
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review.
Liu YF; Zhang ZC; Wang SY; Fu SQ; Cheng XF; Chen R; Sun T
Int Immunopharmacol; 2022 Sep; 110():108900. PubMed ID: 35753122
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Simonaggio A; Epaillard N; Pobel C; Moreira M; Oudard S; Vano YA
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435262
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.
Hsu SK; Li CY; Lin IL; Syue WJ; Chen YF; Cheng KC; Teng YN; Lin YH; Yen CH; Chiu CC
Theranostics; 2021; 11(18):8813-8835. PubMed ID: 34522213
[TBL] [Abstract][Full Text] [Related]
15. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X; Chen L; Li Y; Hu Z; He F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):273-285. PubMed ID: 35288298
[TBL] [Abstract][Full Text] [Related]
17. Programmed necrosis in heart disease: Molecular mechanisms and clinical implications.
Zhu H; Sun A
J Mol Cell Cardiol; 2018 Mar; 116():125-134. PubMed ID: 29426003
[TBL] [Abstract][Full Text] [Related]
18. Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis.
Chen J; Wei Z; Fu K; Duan Y; Zhang M; Li K; Guo T; Yin R
Biomed Pharmacother; 2022 Jun; 150():112929. PubMed ID: 35429741
[TBL] [Abstract][Full Text] [Related]
19. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients.
Cetin B; Wabl CA; Gumusay O
Curr Treat Options Oncol; 2022 Apr; 23(4):609-629. PubMed ID: 35316480
[TBL] [Abstract][Full Text] [Related]
20. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
